EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unraveling psilocybin’s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression

Magdalena Kolasa, Agnieszka Nikiforuk, Agata Korlatowicz, Joanna Solich, Agnieszka Potasiewicz, Marta Dziedzicka-Wasylewska, Ryszard Bugno, Adam Hogendorf, Andrzej Bojarski, Agata Faron-Górecka

Psychopharmacology · 2025

DOI: 10.1007/s00213-024-06644-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychopharmacology, 2025. Verfasst von Magdalena Kolasa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland. Hauptthemen laut MEDLINE: Neuronal Plasticity, Depressive Disorder, Treatment-Resistant, Antidepressive Agents, Behavior, Animal. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Our study aimed to unravel the unknown mechanisms behind the exceptional efficacy of Psilocybin (PSI) in treating treatment-resistant depression (TRD). Focusing on Wistar-Kyoto (WKY) rats with a TRD phenotype and Wistar (WIS) rats as a normative comparison, we investigated behavioral and neuroplasticity-related responses to PSI, striving to shed light on the distinctive features of its antidepressant effects.

Objectives

We set out to assess the behavioral impact of acute and prolonged PSI administration on WKY and WIS rats, employing Novel Object Recognition (NORT), Social Interaction (SI), and Forced Swimming Test (FST). Our secondary objectives involved exploring strain-specific alterations in neuroplasticity-related parameters, including brain-derived neurotrophic factor (BDNF) and activity-regulated cytoskeleton-associated protein (Arc).

Methods

Conducting post-acute and extended assessments after a single PSI administration, we applied behavioral tests and biochemical analyses to measure serum BDNF levels and neuroplasticity-related parameters in the prefrontal cortex. Statistical analyses were deployed to discern significant differences between the rat strains and assess the impact of PSI on behavioral and biochemical outcomes.

Results

Our findings uncovered significant behavioral disparities between WKY and WIS rats, indicating passive behavior and social withdrawal in the former. PSI demonstrated pronounced pro-social and antidepressant effects in both strains, each with its distinctive temporal trajectory. Notably, we identified strain-specific variations in BDNF-related signaling and observed the modulation of Arc expression in WKY rats.

Conclusions

Our study delineated mood-related behavioral nuances between WKY and WIS rat strains, underscoring the antidepressant and pro-social properties of PSI in both groups. The distinct temporal patterns of observed changes and the identified strain-specific neuroplasticity alterations provide valuable insights into the TRD phenotype and the mechanisms underpinning the efficacy of PSI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuronal PlasticityDepressive Disorder, Treatment-ResistantAntidepressive AgentsBehavior, AnimalPsilocybinAnimalsMaleRats, Inbred WKYBrain-Derived Neurotrophic FactorRats, WistarRatsDisease Models, AnimalPrefrontal CortexSpecies SpecificityCytoskeletal ProteinsNerve Tissue Proteins

Stichwörter der Autor:innen

Activity-regulated cytoskeleton-associated protein (Arc)Brain-derived neurotrophic factor (BDNF)Long-term effectNeuroplasticityPsilocybinSocial interactionTreatment-resistant depressionWeight gainWistar Kyoto rats

Substanzen

Brain-Derived Neurotrophic FactorAntidepressive AgentsPsilocybinactivity regulated cytoskeletal-associated proteinBdnf protein, ratCytoskeletal ProteinsNerve Tissue Proteins

Autor:innen und Institutionen

  • Department of Pharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland.
  • Department of Behavioral Neuroscience & Drug Development, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland.
  • Department of Medicinal Chemistry, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland.
  • Department of Pharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland. gorecka@if-pan.krakow.pl.

Förderung

  • Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

Zitieren

APA

Kolasa, M., Nikiforuk, A., Korlatowicz, A., Solich, J., Potasiewicz, A., Dziedzicka-Wasylewska, M., Bugno, R., Hogendorf, A., Bojarski, A., & Faron-Górecka, A. (2025). Unraveling psilocybin’s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression. Psychopharmacology. https://doi.org/10.1007/s00213-024-06644-3

Vancouver

Kolasa M, Nikiforuk A, Korlatowicz A, Solich J, Potasiewicz A, Dziedzicka-Wasylewska M, et al. Unraveling psilocybin’s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression. Psychopharmacology. 2025. doi:10.1007/s00213-024-06644-3

BibTeX
@article{Kolasa2025,
  author = {Kolasa, Magdalena and Nikiforuk, Agnieszka and Korlatowicz, Agata and Solich, Joanna and Potasiewicz, Agnieszka and Dziedzicka-Wasylewska, Marta and Bugno, Ryszard and Hogendorf, Adam and Bojarski, Andrzej and Faron-Górecka, Agata},
  title = {Unraveling psilocybin’s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression},
  journal = {Psychopharmacology},
  year = {2025},
  doi = {10.1007/s00213-024-06644-3}
}
Kostenlos starten →